[Can the hormone-resistance of cancer of the prostate be predicted from the initial biopsy?].
We present 271 prostatic adenocarcinomas with a follow-up of between 11.5 and 18 years, treated by palliative hormone therapy. Multivariate analysis defines three groups. Group 1 (78 cases): with a normal survival; Groups II and III: with poor survival. In this group, treatment is ineffective.
Service d'Urologie, CHU Besançon.
H
H
Bittard
J P
JP
Carbillet
A
A
Jeldi
E
E
Khenifar
M
M
Shikfa
H
H
Wenzel
F
F
Bretillot
M
M
Bittard
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D001706:Biopsy; D004967:Estrogens / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D008297:Male; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D016019:Survival Analysis
D004967:Estrogens
Peut-on prévoir l'hormono-résistance d'un cancer de prostate à partir de la biopsie initiale?